The Effect of Anticholinergics for Prevention of Storage Symptoms After Prostate Photovaporization
Vol. 16 No. 06 (2019),
24 December 2019
Purpose: To evaluate the efficacy of oral anticholinergics as a preventive strategy of storage symptoms and urinary incontinence associated with the early postoperative period after Greenlight laser photovaporization of the prostate (PVP). To analyze potential variables related to the onset of these symptoms.
Materials and methods: Retrospective study of 105 patients who underwent PVP using a 180-W Greenlight laser (XPS). Patients were divided into two groups, depending on whether they were or weren´t prescribed anticholinergics when discharged (oral solifenacin 5 mg for 1 month after surgery). Differences between both groups were analyzed according to IPSS, ICIQ-SF and OABq-SF scores at 1 and 6 months. The potentially predictive variables of the symptomatology after undergoing PVP that we analyzed included age, prostate volume, PSA, IPSS, ICIQ-SF, OABq-SF, Qmax, previous use of a permanent urinary catheter, energy used, and laser application time.
Results: 58 patients in the group with anticholinergics and 47 in the group without anticholinergics were compared. No significant differences were observed between both groups in IPSS (p = .521), ICIQ-SF (p = .720) or OABq-SF (p = .851) at 1 and 6 months after surgery. Regardless of the use of anticholinergics, there was a significant score improvement between the first and second checkup in all the questionnaires: there was a significant decrease in the mean IPSS (p < .001) and the mean score of the eighth IPSS question on patient’s quality of life (p = .026), ICIQ- SF (p = .010) and OAB-q related to symptoms (p = .001) as well as a significant increase in the mean OAB-q score regarding quality of life (p = .005). None of the variables analyzed showed a significant relation to the storage-symptom rate, rate of incontinence, or ICIQ-SF and OABq-SF scores.
Conclusions: The use of solifenacin 5 mg after Greenlight laser PVP is not an effective preventive treatment for storage and incontinence symptoms associated with this procedure, which seem to self-limit over time.
How to Cite
Oelke M, Bachmann A, Descazeaud A et al. EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction. Eur Urol 2013; 64:118-40.
McVary KT, Roehrborn CG, Avins AL et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011; 185:1793-803.
Amón Sesmero JH. Nuevas Perspectivas de la Laserterapia. Arch Esp Urol 2008; 61:1163-9.
Ahyai SA, Gilling P, Kaplan SA et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol 2010; 58:384–97.
Bachmann A, Tubaro A, Barber N et al. 180-W XPS GreenLight Laser Vaporisation Versus Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 6-Month Safety and Efficacy Results of a European Multicentre Randomised Trial—The GOLIATH Study. Eur Urol 2014; 65:931-42.
Cornu JN, Ahyai S, Bachmann A et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol 2015; 67:1066–96.
Audouin M, Benbouzid S, Terrasa JB et al. Evaluation of postoperative symptoms after GreenlightTM photovaporization of the prostate through a dedicated questionnaire [in French]. Prog Urol 2016; 26:108–14.
Cornu JN, Herrmann T, Traxer O et al. Prevention and Management Following Complications from Endourology Procedures. Eur Urol Focus 2 2016; 49-59.
Yu X, Elliott SP, Wilt TJ et al. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. J Urol 2008; 180:241–5, discussion 245.
Thomas JA, Tubaro A, Barber N et al. A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study. Eur Urol 2016; 69:94–102.
Capitán Manjón C, de la Gallega Moreno JM, de la Peña Zarzuelo E et al. Papel actual de la fotovaporización prostática con Láser Greenlight HPS. Aspectos técnicos y revisión de la literatura. Actas Urol Esp 2009; 33(7):771-77.
Ruszat R, Seitz M, Wyler SF et al. GreenLight laser vaporisation of the prostate: single center experience and long-term results after 500 procedures. Eur Urol 2008; 54:893–901.
Bachmann A, Tubaro A, Barber N et al. A European Multicenter Randomized Noninferiority Trial Comparing 180 WGreenLight XPS Laser Vaporization and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: 12-Month Results of the GOLIATH Study. J Urol 2015; 193:570-78.
Knutson T, Edlund C, Fall M et al. BPH with coexisting overactive bladder dysfunction--an everyday urological dilemma. Neurourol Urodyn. 2001; 20(3):237-47.
- Abstract Viewed: 471 times
- pdf/4297 Downloaded: 170 times